Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side
effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically …

Guidelines promote high quality cancer care. Rehabilitation recommendations in oncology
guidelines have not been characterized and may provide insight to improve integration of …

The ubiquitin proteasome system (UPS) degrades individual proteins in a highly regulated
fashion and is responsible for the degradation of misfolded, damaged, or unneeded cellular …

When peripheral neuropathy occurs due to chemotherapy treatment, it is referred to as
chemotherapy-induced peripheral neuropathy (CIPN). Typically, symptoms are sensory …

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and is often
diagnosed at an unresectable advanced stage. Systemic chemotherapy as well as …

Background Chemotherapy-induced peripheral neuropathy (CIPN) is the most common
neurological and clinically relevant side effect of many commonly used chemotherapeutic …

Platinum‐induced peripheral neurotoxicity (PIPN) is a common side effect of platinum‐
based chemotherapy that may cause dose reduction and discontinuation, with oxaliplatin …

Currently, neuropathic pain is an underestimated socioeconomic health problem affecting
millions of people worldwide, which incidence may increase in the next years due to …

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a commonly
encountered disease entity following chemotherapy for cancer treatment. Although only …